Clinical Trial · NCT03583528

Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients

Overview

Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Somatostatin receptor scintigraphy and conventional imaging are used to detect NETs. This study proposes 68Gallium(68Ga)-DOTATOC positron emission tomography/computed tomography (PET/CT) is superior to current imaging techniques. The goal is to evaluate the safety and sensitivity of 68Ga-DOTATOC PET/CT at detecting NETs and other tumors with over-expression of somatostatin receptors.

Sponsor

British Columbia Cancer Agency

Phase

N/A

Contacts

Heather Saprunoff

hsaprunoff@bccancer.bc.ca

604-877-6000 ext 2818

ClinicalTrials.gov

NCT03583528

Drug / Compound

Isotope(s):
Target(s):